Renovaro Inc. (RENB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, Renovaro reported revenue of $51,992. Net income was -$3.6M (a -6852.0% net margin), or -$1.06 per diluted share. Gross margin was 100.0% and operating margin was -16729.4%. Operating activities generated -$5.3M of cash, leaving -$5.3M of free cash flow. At fiscal year end, Renovaro held $9.9M in total assets against $19.0M in total liabilities, including $1.7M of cash and equivalents.
Open the full interactive Renovaro financials → Quarterly statements, key ratios, valuation history and price charts.
Renovaro Key Stats
| Share Price | $1.03 |
|---|---|
| Market Cap | $3.5M |
| 52-Week Range | $1.03 – $12.00 |
| Shares Outstanding | 3.4 million (basic, 2026 Q4) |
Renovaro Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $51,992 |
| Gross Profit | — | — | — | — | — | $51,992 |
| Operating Income | -$23.4M | -$116.1M | -$38.6M | -$81.6M | -$189.0M | -$8.7M |
| Pre-Tax Income | -$26.8M | -$113.4M | -$39.7M | -$80.7M | -$178.0M | -$3.6M |
| Income Tax | -$125,276 | $34 | — | — | $1,474 | $1,406 |
| Net Income | -$26.7M | -$113.4M | -$39.7M | -$80.7M | -$178.0M | -$3.6M |
| Diluted EPS | -$45.60 | — | -$56.80 | -$67.20 | -$86.40 | -$1.06 |
Renovaro Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $20,942 | $31,050 |
| Net Income | $2.8M | -$1.8M | -$2.6M | -$2.0M |
| Diluted EPS | $1.04 | -$0.64 | -$0.80 | -$0.60 |
Renovaro Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.7M | $9.2M | $1.9M | $220,467 | $92,700 | $1.7M |
| Current Assets | $20.9M | $9.6M | $2.6M | $2.0M | $1.0M | $2.0M |
| Total Assets | $189.6M | $84.6M | $58.3M | $163.1M | $8.2M | $9.9M |
| Current Liabilities | $1.9M | $6.5M | $11.0M | $30.3M | $29.2M | $18.9M |
| Total Long-Term Debt | $4.6M | $4.6M | — | $245,000 | $3.6M | $388,335 |
| Total Liabilities | $14.9M | $12.0M | $11.8M | $31.2M | $29.6M | $19.0M |
| Shareholders' Equity | $174.7M | $72.6M | $46.5M | $132.0M | -$21.3M | -$9.0M |
Renovaro Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$20.6M | -$15.7M | -$11.8M | -$11.0M | -$7.9M | -$5.3M |
| Cash From Investing | -$48,892 | -$5,156 | -$29,774 | -$1.3M | -$500,000 | $543,462 |
| Cash From Financing | $32.6M | $4.3M | $4.5M | $10.5M | $8.4M | $6.4M |
| Free Cash Flow | -$20.7M | -$15.7M | -$11.8M | -$11.0M | -$7.9M | -$5.3M |
Figures from Renovaro's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Renovaro financials page for every line item.
Renovaro Company Profile
| Ticker | RENB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Suite 906 Los Angeles, California |
| Incorporated in | Delaware |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001527728 |
Frequently Asked Questions
What was Renovaro's revenue in fiscal 2026?
Renovaro (RENB) reported revenue of $51,992 for fiscal 2026.
What is Renovaro's annual revenue history?
Renovaro's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0; 2026: $51,992.
What was Renovaro's net income in fiscal 2026?
Renovaro reported net income of -$3.6M for fiscal 2026.
What was Renovaro's earnings per share (EPS) in fiscal 2026?
Renovaro's diluted EPS was -$1.06 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Renovaro generate in fiscal 2026?
Renovaro generated -$5.3M of free cash flow in fiscal 2026.
What was Renovaro's revenue last quarter?
In its most recent reported quarter (2026 Q4), Renovaro reported revenue of $31,050.
How much debt does Renovaro have?
Renovaro reported $388,335 of long-term debt, including the current portion, at the end of fiscal 2026.
How many shares of Renovaro are outstanding?
Renovaro reported a weighted average of 3.4 million basic shares outstanding in 2026 Q4.
What is Renovaro's market cap?
Based on its latest closing price, Renovaro (RENB) has a market capitalization of about $3.5M.
When does Renovaro's fiscal year end?
Renovaro's fiscal year end, as registered with the SEC, is June 30.
Where is Renovaro headquartered?
Renovaro lists its business address in Suite 906 Los Angeles, California in its SEC filings.